Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2015

Content

| 1. General Methods | 2 |
|-------------------------------------------------------------------------|----|
| 2. Materials | 2 |
| 3. General procedure | 2 |
| 4. Characterization Data | 3 |
| 5. References | g |
| 6. Copies of NMR spectra and HPLC measurements of the products 3 | 10 |

1. General Methods

The products were purified by column chromatography on Merck silica gel 60, particle size 0.040-0.063 mm (230-240 mesh, flash). For thin-layer chromatography (TLC) analysis, SIL G-25 UV254 from MACHEREY&NAGEL were used. Visualization of the developed TLC plates was performed with ultraviolet irradiation (254 nm). ¹H- and ¹³C-NMR spectra were recorded at ambient temperature on Inova 400 or VNMRS 600 instruments with tetramethylsilane as an internal standard. Mass spectra and high resolution mass spectra were acquired on a Finnigan MAT 95 (EI/CI) or on a ThermoFisher Scientific LTQ Orbitrap XL (ESI). IR spectra were taken on a PerkinElmer Spectrum 100 FT-IR Spectrometer. Microanalyses were performed with a Vario EL element analyser. Optical rotation values were measured on a Perkin-Elmer 241 polarimeter. Analytical HPLC was performed on a Hewlett-Packard 1100 Series instrument using chiral stationary phases [Daicel AD, Daicel AS, Daicel OD, Daicel OJ, Daicel (s,s)-Whelk O1 or Daicel Whelk.M].

2. Materials

All reactions were carried out under argon. Toluene and mesitylene were distilled over Solvona[®]. Dry dichloromethane was purchased from Acros. All other chemicals were used without further purification. Triazolium salts **A-G** were prepared according to known literature procedures.^[1] The corresponding α,β -unsaturated N-acyltriazoles **2** were prepared according to the literature.^[2] Racemic samples were prepared with precatalyst **A**.

3. General procedure

To a dried and argon-filled Schlenk flask was added 1,3-dicarbonyl compound 1 (0.5 mmol, 1.0 equiv.), α , β -unsaturated N-acyltriazole 2 (1.0 mmol, 2.0 equiv.), triazolium salt **D** (0.1 mmol, 20 mol%) and 3 Å MS (100 mg) in toluene (5 mL). The mixture was cooled down to -5 °C and then K_2CO_3 (0.2 mmol, 40 mol%) was added. After stirring for 48 h at -5 °C, the solution was directly purified by flash chromatography on silica gel (n-pentane/Et₂O 4:1 or DCM) to afford the products **3a-o**.

4. Characterization Data

The compound **3a** was prepared according to the general procedure. The product was obtained as colorless oil (105.6 mg, 66% yield). The ee (86%) was measured by HPLC using a chiral stationary phase [Daicel AS, *n*-heptane:EtOH = 9:1, 1.0 mL/min), $t_R = 11.13$ min (major), 9.27 min (minor)], $[\alpha]_D^{21} = +70.7$ (c = 1.0, CHCl₃).

 1 H NMR (600 MHz, CDCl₃) δ 7.53 - 7.51 (m, 2H), 7.47 - 7.40 (m, 3H), 7.35 - 7.33 (m, 2H), 7.29 - 7.26 (m, 3H), 4.41 (dd, J = 7.7, 2.5 Hz, 1H), 3.98 - 3.89 (m, 2H), 3.11 (dd, J = 15.9, 7.7 Hz, 1H), 2.94 (dd, J = 15.9, 2.5 Hz, 1H), 0.88 (t, J = 7.1 Hz, 3H) ppm; 13 C NMR (151 MHz, CDCl₃) δ 166.35, 166.00, 158.52, 139.89, 133.08, 130.13, 129.19 (2C), 128.63 (2C), 127.99 (2C), 127.74, 126.74 (2C), 111.69, 61.00, 38.84, 36.31, 13.45 ppm.

MS (EI, 70 eV) m/z (%): 322 [M⁺] (60), 294 (18), 279 (20), 248 (45), 220 (23), 105 (100), 77 (35). IR (ATR): 2984, 2324, 2097, 1891, 1778, 1704, 1448, 1300, 1238, 1067, 846, 755, 698 cm⁻¹. HRMS (EI): calcd for $C_{20}H_{18}O_4$ [M⁺]: 322.1200; found: 322.1203.

The compound **3b** was prepared according to the general procedure. The product was obtained as colorless oil (125.0 mg, 71% yield). The ee (82%) was measured by HPLC using a chiral stationary phase [Daicel AD, *n*-heptane:*i*-PrOH = 9:1, 1.0 mL/min), $t_R = 13.48$ min (major), 10.58 min (minor)], $[\alpha]_D^{21} = +46.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.51 - 7.45 (m, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.29 - 7.22 (m, 3H), 6.95 - 6.89 (m, 2H), 4.39 (dd, J = 7.7, 2.5 Hz, 1H), 4.02 - 3.93 (m, 2H), 3.85 (s, 3H), 3.08 (dd, J = 15.8, 7.6 Hz, 1H), 2.92 (dd, J = 15.9, 2.5 Hz, 1H), 0.95 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.63, 166.24, 161.12, 158.29, 140.05, 130.34 (2C), 129.14 (2C), 127.66, 126.74 (2C), 125.15, 113.32 (2C), 110.60, 60.96, 55.37, 38.97, 36.39, 13.65 ppm.

MS (EI, 70 eV) m/z (%): 352 [M⁺] (72), 278 (14), 135 (100), 77 (22).

IR (ATR): 2969, 2315, 2095, 1901, 1775, 1703, 1610, 1507, 1242, 1059, 840, 767, 702, 541 cm $^{-1}$. HRMS (ESI): calcd for $C_{21}H_{20}O_5$ [M+Na] $^+$: 375,1203; found: 375.1201.

The compound **3c** was prepared according to the general procedure. The product was obtained as light yellow oil (168.1 mg, 94% yield). The ee (76%) was measured by HPLC using a chiral

stationary phase [Daicel AD, *n*-heptane:*i*-PrOH = 9:1, 1.0 mL/min), t_R = 9.43 min (major), 7.73 min (minor)], $[\alpha]_D^{21} = +63.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.48 - 7.44 (m, 2H), 7.41 - 7.38 (m, 2H), 7.34 (t, J = 7.4 Hz, 2H), 7.30 - 7.26 (m, 1H), 7.23 (d, J = 7.4 Hz, 2H), 4.40 (dd, J = 7.7, 2.5 Hz, 1H), 4.00 - 3.91 (m, 2H), 3.09 (dd, J = 15.9, 7.7 Hz, 1H), 2.94 (dd, J = 16.0, 2.5 Hz, 1H), 0.93 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 165.96, 165.70, 157.38, 139.69, 136.25, 131.43, 130.08 (2C), 129.23 (2C), 128.27 (2C), 127.82, 126.68 (2C), 112.10, 61.16, 38.85, 36.19, 13.55 ppm.

MS (EI, 70 eV) m/z (%): 356 [M⁺] (74), 313 (27), 282 (40), 254 (24), 139 (100), 111 (31).

IR (ATR): 2982, 2320, 2092, 1910, 1781, 1706, 1486, 1299, 1241, 1070, 991, 845, 753, 698 cm $^{-1}$. HRMS (EI): calcd for $C_{20}H_{17}ClO_4$ [M] $^+$: 356.0810; found: 356.0812.

The compound **3d** was prepared according to the general procedure. The product was obtained as yellow oil (176.2 mg, 96% yield). The ee (62%) was measured by HPLC using a chiral stationary phase [Daicel (s,s)-Whelk O1, *n*-heptane:EtOH = 7:3, 0.5 mL/min), $t_R = 17.08$ min (major), 14.00 min (minor)], $[\alpha]_D^{21} = +70.8$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 8.28 - 8.25 (m, 2H), 7.71 - 7.67 (m, 2H), 7.37 - 7.33 (m, 2H), 7.31 - 7.27 (m, 1H), 7.26 - 7.22 (m, 2H), 4.44 (dd, J = 7.7, 2.6 Hz, 1H), 3.96 (q, J = 7.1 Hz, 2H), 3.14 (dd, J = 16.0, 7.7 Hz, 1H), 2.98 (dd, J = 16.0, 2.6 Hz, 1H), 0.92 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 165.22, 165.07, 156.27, 148.51, 139.37, 139.20, 129.89 (2C), 129.33 (2C), 127.99, 126.63 (2C), 123.21 (2C), 113.61, 61.40, 38.82, 36.00, 13.55 ppm.

MS (EI, 70 eV) m/z (%): 367 [M⁺] (55), 324 (42), 293 (51), 265 (30), 150 (90), 104 (100), 92 (46), 76 (84).

IR (ATR): 2986, 2321, 2095, 1923, 1784, 1708, 1600, 1518, 1342, 1244, 1074, 989, 856, 749, 698 cm⁻¹.

HRMS (EI): calcd for C₂₀H₁₇NO₆ [M]⁺: 367.1050; found: 367.1051.

The compound **3e** was prepared according to the general procedure. The product was obtained as light yellow oil (153.3 mg, 77% yield). The ee (79%) was measured by HPLC using a chiral stationary phase [Daicel AD, n-heptane:i-PrOH = 7:3, 0.7 mL/min), t_R = 14.19 min (major), 9.95 min (minor)], [α]_D²¹ = +81.0 (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.67 - 7.65 (m, 2H), 7.51 - 7.47 (m, 1H), 7.36 - 7.32 (m, 2H), 7.28 - 7.21 (m, 3H), 7.15 - 7.11 (m, 2H), 4.17 (dd, J = 7.7, 3.1 Hz, 1H), 4.09 - 4.02 (m, 1H), 4.01 - 3.95 (m, 1H), 3.17 (dd, J = 16.2, 7.7 Hz, 1H), 3.03 (dd, J = 16.2, 3.1 Hz, 1H), 1.01 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 192.97, 164.91, 159.66, 140.29, 137.38, 136.11, 133.55, 129.33 (2C), 128.67 (2C), 128.60 (2C), 128.35, 128.18, 127.10 (2C), 62.48, 41.18, 35.15, 13.49

ppm.

MS (EI, 70 eV) m/z (%): 350 [M⁺] (20), 277 (51), 235 (40), 105 (100), 77 (51).

IR (ATR): 2923, 2661, 2324, 2167, 2089, 1984, 1910, 1783, 1733, 1664, 1594, 1495, 1450, 1371, 1307, 1275, 1163, 1126, 1014, 957, 913, 856, 762, 698 cm⁻¹.

HRMS (ESI): calcd for $C_{21}H_{18}O_5$ [M+Na]+: 373.1046; found: 373.1041.

The compound **3f** was prepared according to the general procedure. The product was obtained as colorless oil (109.5 mg, 75% yield). The ee (81%) was measured by HPLC using a chiral stationary phase [Daicel OJ, *n*-heptane:EtOH = 8:2, 1.0 mL/min), $t_R = 23.61$ min (major), 17.37 min (minor)], $[\alpha]_D^{21} = +62.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.64 - 7.61 (m, 2H), 7.53 - 7.50 (m, 1H), 7.41 - 7.37 (m, 2H), 7.28 - 7.24 (m, 2H), 7.23 - 7.18 (m, 1H), 7.16 - 7.12 (m, 2H), 4.32 (dd, J = 7.3, 2.9 Hz, 1H), 3.06 (dd, J = 16.0, 7.6 Hz, 1H), 2.93 (dd, J = 16.0, 3.6 Hz, 1H), 1.90 (d, J = 1.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 195.77, 166.49, 154.73, 139.95, 138.40, 133.06, 129.13 (2C), 128.78 (2C), 128.71 (2C), 127.62, 126.75 (2C), 117.74, 39.41, 36.19, 19.01 ppm.

MS (EI, 70 eV) m/z (%): 293 [M⁺] (60), 274 (19), 264 (56), 249 (18), 221 (30), 207 (21), 173 (51), 105 (100), 77 (48).

IR (ATR): 3028, 2099, 1777, 1641, 1598, 1493, 1446, 1384, 1315, 1224, 1175, 1116, 1032, 986, 899, 856, 805, 755, 698 cm⁻¹.

HRMS (EI): calcd for C₁₉H₁₆O₃ [M]⁺: 292.1094; found: 292.1103.

The compound **3g** was prepared according to the general procedure. The product was obtained as a colorless solid (95.0 mg, 65% yield). The ee (82%) was measured by HPLC using a chiral stationary phase [Daicel Whelk.M, n-heptane:EtOH = 7:3, 0.7 mL/min), t_R = 14.19 min (major), 8.34 min (minor)], $\lceil \alpha \rceil_D^{21} = +14.8$ (c = 1.0, CHCl₃). Melting point: 120 - 123 °C.

¹H NMR (600 MHz, CDCl₃) δ 7.52 - 7.47 (m, 2H), 7.39 - 7.35 (m, 2H), 7.32 - 7.25 (m, 4H), 7.25 - 7.19 (m, 2H), 7.19 - 7.14 (m, 1H), 7.14 - 7.05 (m, 4H), 4.56 (dd, J = 7.9, 2.4 Hz, 1H), 3.21 (dd, J = 15.9, 7.9 Hz, 1H), 3.06 (dd, J = 15.9, 2.4 Hz, 1H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 195.90, 166.67, 154.81, 139.70, 137.07, 132.59, 131.96, 130.29, 129.24 (2C), 129.22 (2C), 128.98 (2C), 128.05 (2C), 127.99 (2C), 127.78, 126.84 (2C), 118.27, 40.38, 35.95 ppm.

MS (EI, 70 eV) m/z (%): 354 [M⁺] (9), 105 (100), 77 (92).

IR (ATR): 3061, 3030, 2105, 1778, 1640, 1493, 1448, 1411, 1323, 1249, 1187, 1113, 1025, 987, 900, 843, 757, 730, 696 cm⁻¹.

HRMS (EI): calcd for $C_{24}H_{18}O_3$ [M]⁺: 354.1251; found: 354.1251.

The compound **3h** was prepared according to the general procedure. The product was obtained as a colorless solid (78.5 mg, 68% yield). The ee (80%) was measured by HPLC using a chiral stationary phase [Daicel (s,s)-Whelk O1, *n*-heptane:EtOH = 9:1, 1.0 mL/min), $t_R = 11.63$ min (major), 9.93 min (minor)], $[\alpha]_D^{21} = +36.6$ (c = 1.0, CHCl₃). Melting point: 68 - 69 °C.

 1 H NMR (600 MHz, CDCl₃) δ 7.34 - 7.30 (m, 2H), 7.28 - 7.24 (m, 1H), 7.15 - 7.11 (m, 2H), 4.17 - 4.11 (m, 1H), 2.95 (dd, J = 15.7, 7.3 Hz, 1H), 2.82 (dd, J = 15.7, 2.6 Hz, 1H), 2.41 (d, J = 1.1 Hz, 3H), 2.11 (s, 3H) ppm; 13 C NMR (151 MHz, CDCl₃) δ 197.88, 165.59, 160.24, 139.69, 129.42 (2C), 127.92, 126.64 (2C), 117.26, 38.83, 37.16, 29.76, 19.07 ppm.

MS (EI, 70 eV) m/z (%): 230 [M⁺] (35), 212 (42), 202 (48), 187 (76), 145 (57), 131 (100), 115 (55), 103 (58), 91 (31), 77 (70), 51 (59).

IR (ATR): 2920, 2089, 1781, 1688, 1609, 1492, 1450, 1423, 1359, 1291, 1268, 1242, 1172, 1114, 1025, 943, 863, 770, 702, 660 cm⁻¹.

Anal. calcd. for C₁₄H₁₄O₃ (230) C, 73.03; H, 6.13; found: C, 72.93; H, 6.04.

The compound **3i** was prepared according to the general procedure. The product was obtained as a colorless solid (105.3 mg, 81% yield). The ee (85%) was measured by HPLC using a chiral stationary phase [Daicel (s,s)-Whelk O1, *n*-heptane:EtOH = 7:3, 0.7 mL/min), $t_R = 6.80$ min (major), 5.79 min (minor)], $[\alpha]_D^{21} = +202.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.31 - 7.28 (m, 2H), 7.25 - 7.22 (m, 1H), 7.15 - 7.12 (m, 2H), 4.27 - 4.24 (m, 1H), 4.15 - 4.12 (m, 2H), 2.95 (dd, J = 15.9, 7.6 Hz, 1H), 2.83 (dd, J = 15.9, 2.2 Hz, 1H), 2.47 (d, J = 1.0 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.13, 165.93, 161.31, 140.60, 129.01 (2C), 127.48, 126.58 (2C), 109.99, 60.85, 37.82, 36.36, 18.88, 14.05 ppm.

MS (EI, 70 eV) m/z (%): 260 [M⁺] (40), 217 (32), 186 (48), 171 (23), 158 (90), 144 (24), 131 (75), 115 (93), 103 (85), 91 (47), 77 (100).

IR (ATR): 2987, 2280, 2213, 2126, 2084, 2017, 1775, 1710, 1644, 1494, 1452, 1369, 1281, 1242, 1175, 1122, 1066, 972, 864, 764, 705, 668 cm⁻¹.

HRMS (EI): calcd for $C_{15}H_{16}O_4$ [M]⁺: 260.1046; found: 260.1043.

The compound 3j was prepared according to the general procedure. The product was obtained as a colorless solid (100.0 mg, 62% yield). The ee (83%) was measured by HPLC using a chiral stationary phase [Daicel (s,s)-Whelk O1, n-heptane:EtOH = 7:3, 0.7 mL/min), t_R = 7.80 min

(major), 6.58 min (minor)], $[\alpha]_D^{21} = +55.8$ (c = 1.0, CHCl₃). Melting point: 92 - 95 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.32 - 7.20 (m, 6H), 7.15 - 7.02 (m, 4H), 5.14 - 5.04 (m, 2H), 4.26 (d, J = 7.3 Hz, 1H), 2.93 (dd, J = 15.8, 7.6 Hz, 1H), 2.80 (dd, J = 15.8, 2.2 Hz, 1H), 2.47 (d, J = 1.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.89, 165.66, 162.02, 140.50, 135.55, 129.05 (2C), 128.45 (2C), 128.13, 127.85 (2C), 127.53, 126.62 (2C), 109.58, 66.54, 37.87, 36.36, 18.93 ppm.

MS (EI, 70 eV) m/z (%): 322 [M⁺] (1), 231 (19), 91 (100).

IR (ATR): 3063, 3028, 2320, 2204, 2083, 2010, 1901, 1778, 1710, 1638, 1492, 1449, 1379, 1285, 1228, 1177, 1114, 1065, 864, 798, 701 cm⁻¹.

Anal. calcd. for C₂₀H₁₈O₄ (322) C, 74.52; H, 5.63; found: C, 74.39; H, 5.65.

The compound **3k** was prepared according to the general procedure. The product was obtained as colorless oil (114.4 mg, 88% yield). The ee (83%) was measured by HPLC using a chiral stationary phase [Daicel (s,s)-Whelk O1, *n*-heptane:EtOH = 9:1, 1.0 mL/min), $t_R = 6.78$ min (major), 5.68 min (minor)], $[\alpha]_D^{21} = +152.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.33 - 7.27 (m, 2H), 7.26 - 7.21 (m, 1H), 7.14 - 7.09 (m, 2H), 4.25 (dd, J = 7.7, 2.1 Hz, 1H), 3.67 (d, J = 1.3 Hz, 3H), 2.96 - 2.87 (m, 2H), 2.87 - 2.78 (m, 2H), 1.27 (td, J = 7.5, 0.8 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.36, 166.23, 166.19, 140.34, 129.07 (2C), 127.52, 126.51 (2C), 108.94, 51.91, 37.70, 36.52, 25.47, 11.78 ppm.

MS (EI, 70 eV) m/z (%): 260 [M⁺] (66), 228 (53), 217 (19), 203 (40), 200 (73), 189 (100), 172 (29), 157 (20), 131 (23), 121 (70), 115 (29), 57 (24).

IR (ATR): 3025, 2109, 1782, 1711, 1643, 1436, 1352, 1282, 1215, 1171, 1114, 1052, 975, 941, 866, 751, 701, 666 cm⁻¹.

HRMS (EI): calcd for C₁₅H₁₆O₄ [M]⁺: 260.1043; found: 260.1050.

The compound **31** was prepared according to the general procedure. The product was obtained as a white solid (109.2 mg, 65% yield). The ee (77%) was measured by HPLC using a chiral stationary phase [Daicel OD, *n*-heptane:*i*-PrOH = 9:1, 0.7 mL/min), t_R = 11.10 min (major), 12.78 min (minor)], $[\alpha]_D^{21} = +65.4$ (c = 1.0, CHCl₃). Melting point: 92 - 94 °C.

¹H NMR (600 MHz, CDCl₃) δ 7.54 - 7.49 (m, 2H), 7.47 - 7.38 (m, 3H), 7.14 (s, 4H), 4.37 (dd, J = 7.7, 2.4 Hz, 1H), 3.98 - 3.89 (m, 2H), 3.08 (dd, J = 15.8, 7.7 Hz, 1H), 2.92 (dd, J = 15.8, 2.4 Hz, 1H), 2.32 (s, 3H), 0.89 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.40, 166.10, 158.31, 137.40, 136.84, 133.14, 130.06, 129.84 (2C), 128.62 (2C), 127.95 (2C), 126.60 (2C),

111.91, 60.96, 38.48, 36.41, 21.04, 13.45 ppm.

MS (EI, 70 eV) m/z (%): 336 [M⁺] (46), 279 (18), 262 (32), 234 (20), 105 (100), 77 (59).

IR (ATR): 3921, 3784, 3472, 2983, 2654, 2319, 2079, 1993, 1912, 1784, 1708, 1645, 1512, 1449, 1368, 1303, 1233, 1187, 1112, 1069, 988, 853, 769, 698 cm⁻¹.

Anal. calcd. for $C_{21}H_{20}O_4$ (336) C, 74.98; H, 5.99; found: C, 74.82; H, 6.03.

The compound **3m** was prepared according to the general procedure. The product was obtained as a colorless solid (119.5 mg, 67% yield). The ee (79%) was measured by HPLC using a chiral stationary phase [Daicel AD, *n*-heptane:*i*-PrOH = 9:1, 1.0 mL/min), $t_R = 11.94$ min (major), 8.66 min (minor)], $[\alpha]_D^{21} = +55.0$ (c = 1.0, CHCl₃). Melting point: 69 - 71 °C.

¹H NMR (600 MHz, CDCl₃) δ 7.52 - 7.48 (m, 2H), 7.48 - 7.44 (m, 1H), 7.44 - 7.39 (m, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 4.38 (dd, J = 7.8, 2.3 Hz, 1H), 4.00 - 3.89 (m, 2H), 3.10 (dd, J = 15.9, 7.7 Hz, 1H), 2.91 (dd, J = 15.9, 2.3 Hz, 1H), 0.88 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.20, 165.64, 158.87, 138.41, 133.63, 132.86, 130.27, 129.38 (2C), 128.61 (2C), 128.15 (2C), 128.01 (2C), 111.23, 61.11, 38.29, 36.14, 13.45 ppm.

MS (EI, 70 eV) m/z (%): 356 [M⁺] (29), 282 (28), 105 (100), 77 (51).

IR (ATR): 3386, 2982, 2660, 2324, 2112, 1908, 1781, 1702, 1644, 1490, 1445, 1409, 1371, 1341, 1303, 1238, 1183, 1109, 1066, 989, 849, 765, 729, 696 cm⁻¹.

HRMS (EI): calcd for C₂₀H₁₇ClO₄ [M]⁺: 356.0810; found: 356.0813.

The compound **3n** was prepared according to the general procedure. The product was obtained as a colorless solid (150.2 mg, 78% yield). The ee (76%) was measured by HPLC using a chiral stationary phase [Daicel AD, n-heptane:i-PrOH = 9:1, 1.0 mL/min), t_R = 12.83 min (major), 9.23 min (minor)], [α]_D²¹ = +47.5 (c = 1.0, CHCl₃). Melting point: 91 - 93 °C.

¹H NMR (600 MHz, CDCl₃) δ 7.52 - 7.48 (m, 2H), 7.48 - 7.43 (m, 3H), 7.43 - 7.38 (m, 2H), 7.16 - 7.11 (m, 2H), 4.37 (dd, J = 7.7, 2.4 Hz, 1H), 3.99 - 3.89 (m, 2H), 3.10 (dd, J = 15.9, 7.8 Hz, 1H), 2.90 (dd, J = 15.9, 2.4 Hz, 1H), 0.88 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 166.16, 165.59, 158.90, 138.98, 132.88, 132.32 (2C), 130.27, 128.61 (2C), 128.51 (2C), 128.01 (2C), 121.71, 111.16, 61.10, 38.36, 36.05, 13.45 ppm.

MS (EI, 70 eV) m/z (%): 400 [M+] (6), 105 (100), 77 (74).

IR (ATR): 2982, 2322, 2082, 1903, 1781, 1703, 1642, 1487, 1407, 1299, 1237, 1182, 1110, 1066, 993, 940, 843, 766, 696 cm⁻¹.

Anal. calcd. for C₂₀H₁₇BrO₄ (400) C, 59.87; H, 4.27; found: C, 59.81; H, 4.31.

The compound **30** was prepared according to the general procedure. The product was obtained as a colorless solid (142.5 mg, 74% yield). The ee (79%) was measured by HPLC using a chiral stationary phase [Daicel OD, n-heptane:i-PrOH = 9:1, 1.0 mL/min), t_R = 12.16 min (major), 8.50 min (minor)], $[\alpha]_D^{21} = +216.0$ (c = 1.0, CHCl₃).

¹H NMR (600 MHz, CDCl₃) δ 7.62 (dd, J = 7.9, 1.2 Hz, 1H), 7.58 - 7.54 (m, 2H), 7.50 - 7.41 (m, 3H), 7.29 (td, J = 7.5, 1.2 Hz, 1H), 7.22 (dd, J = 7.8, 1.7 Hz, 1H), 7.15 (td, J = 7.6, 1.7 Hz, 1H), 4.91 (dd, J = 7.9, 2.4 Hz, 1H), 3.98 - 3.89 (m, 2H), 3.08 (dd, J = 16.0, 7.9 Hz, 1H), 2.99 (dd, J = 16.0, 2.3 Hz, 1H), 0.90 (t, J = 7.1 Hz, 3H) ppm; ¹³C NMR (151 MHz, CDCl₃) δ 165.84, 165.50, 159.86, 138.15, 133.74, 132.76, 130.35, 129.42, 128.69 (2C), 128.30, 128.05 (2C), 127.28, 123.88, 110.66, 61.09, 38.42, 34.74, 13.49 ppm.

MS (EI, 70 eV) m/z (%): 400 [M⁺] (2), 321 (46), 279 (71), 251 (22), 173 (18), 105 (100), 77 (74). IR (ATR): 3061, 2983, 2164, 2067, 1784, 1706, 1645, 1464, 1370, 1343, 1300, 1238, 1186, 1119, 1066, 987, 944, 850, 760, 696 cm⁻¹.

HRMS (ESI): calcd for C₂₀H₁₇BrO₄ [M+Na]⁺: 423.0202; found: 423.0202.


5. References

a) N. E. Wurz, C. G. Daniliuc and F. Glorius, *Chem. Eur. J.*, 2012, **18**, 16297; b) H. U. Vora, S. P. Lathrop, N. T. Reynolds, M. S. Kerr, J. V. R. de Alaniz and T. Rovis, *Org. Synth.*, 2010, **87**, 350; c) J. R. Struble and J. W. Bode, *Org. Synth.*, 2010, **87**, 362; d) K. B. Ling and A. D. Smith, *Chem. Commun.*, 2011, **47**, 373.


[2] G. Speranza , C. F. Morelli, P. Manitto, Synthesis, 2000, 123.

6. Copies of NMR spectra and HPLC measurements of the products 3

¹H NMR of **3a**



¹³C NMR of **3a**



HPLC analysis: rac-3a

24.5 Data file:


D:\ERNIE\NI\94ARAS.D Laufmittel: n-Heptan/EtOH 9:1; Die Probe ist in DCM/LM gelöst Sample Info:

DAICELAS.M Chiralpak AS (250 x 4.6)mm 10μ Säule: Säuleninfo:

Analytik Labor AKEN Operator:


Injektion Time: Injektion Date: 10:25:40 08.01.2015

Instrument Conditions: At Start At Stop Temperature in °C: Pressure in bar: Flow in ml/min: 30.0 31.8 1.0 30.0 32.0 1.0




| 1 | ‡ 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area 8 |
|---|------------|----------------------|-------|-------------------|-------------------|--------|
| | | I | | 1 | 1 | I |
| | 1 | 4.03 | 0.17 | 0.86 | 10.91 | 0.21 |
| | 2 | 4.88 | 0.13 | 3.45 | 29.05 | 0.56 |
| | 3 | 9.11 | 0.36 | 110.42 | 2580.36 | 49.60 |
| Ī | 4 | 10.96 | 0.42 | 95.22 | 2582.19 | 49.63 |
| Т | otal | | | | 5202.51 | 100.00 |

Enantioenriched 3a




| 1 | # | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|----------|----------------------|-------|----------------|-------------------|--------|
| | | | | I | I | |
| -1- | 1 | 9.27 | 0.37 | 20.27 | 485.91 | 7.12 |
| 1 | 2 | 11.13 | 0.44 | 223.99 | 6334.98 | 92.88 |
| T | otal | | | | 6820.89 | 100.00 |

¹H NMR of **3b**



¹³C NMR of **3b**



HPLC analysis: rac-3b

Data file: Sample Info: PACKARD


D:\GONZO\NI\108ARAD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst.

DAICELAD.M Säule:

Chiralpak AD (250x4,6)mm Analytik Labor AKEN Säuleninfo: Operator:


Injektion Time: Injektion Date: 14:17:30 28.01.2015

Instrument Conditions: Temperature in °C: Pressure in bar: Flow in ml/min: At Start 30.0°C 31.9 At Stop 30.0°C 32.9 1.00




| I | ‡ | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|----------|-------------------|-------|----------------|--------------|--------|
| | | | | | | |
| - 1 | 1, | 5.21 | 0.20 | 3.06 | 41.71 | 0.80 |
| i | 2 | 5.91 | 0.18 | 1.08 | 13.10 | 0.25 |
| | 3 | 10.68 | 0.37 | 104.99 | 2593.82 | 49.49 |
| 1 | 4 | 13.58 | 0.48 | 80.71 | 2592.20 | 49.46 |
| T | otal | | | | 5240.84 | 100.00 |

Enantioenriched 3b




| I | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------------|-------------------|-------|----------------|-------------------|--------|
| 1_ | | I | | | | |
| 1 | 1 | 3.70 | 0.13 | 2.99 | 26.00 | 0.24 |
| | 2 | 5.21 | 0.16 | 10.39 | 117.23 | 1.07 |
| | 3 | 5.89 | 0.17 | 19.50 | 232.00 | 2.12 |
| | 4 | 10.58 | 0.35 | 40.95 | 970.68 | 8.87 |
| I | 5 | 13.48 | 0.46 | 310.80 | 9603.18 | 87.71 |
| T | otal | | | | 10949.09 | 100.00 |

 ^{1}H NMR of 3c



¹³C NMR of **3c**



HPLC analysis: rac-3c


Data file: Sample Info: PACKARD

D:\GONZO\NI\107ARAD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst.

DAICELAD.M Chiralpak AD (250x4,6)mm Analytik Labor AKEN Säuleninfo: Operator:


Injektion Time: Injektion Date: 13:54:24 28.01.2015

Instrument Conditions: Temperature in°C: Pressure in bar: Flow in ml/min: At Start 30.0°C 32.0 1.00 At Stop 30.0°C 32.7 1.00




| I | ‡ I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------|-------------------|-------|----------------|-------------------|--------|
| | | | | | | |
| -1 | 1 | 4.50 | 0.11 | 4.89 | 35.78 | 0.50 |
| Ī | 2 | 4.71 | 0.14 | 19.09 | 184.90 | 2.61 |
| 1 | 3 | 7.76 | 0.26 | 195.45 | 3427.11 | 48.36 |
| 1 | 4 | 9.45 | 0.32 | 156.58 | 3378.77 | 47.68 |
| I | 51 | 10.65 | 0.38 | 2.34 | 60.03 | 0.85 |
| T | otal | | | | 7086.59 | 100.00 |

Enantioenriched 3c




| 1 | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|-------|----------------------|-------|----------------|--------------|--------|
| ¦- | | 4.72 | 0.15 | 42.43 | 430.561 | 4.33 |
| i | 2 | 5.13 | 0.37 | 4.62 | 116.64 | 1.17 |
| i | 3 | 7.73 | 0.26 | 58.70 | 1009.51 | 10.16 |
| i | 4 | 9.43 | 0.31 | 357.26 | 7387.30 | 74.31 |
| i | 5 | 10.79 | 0.42 | 1.88 | 54.16 | 0.54 |
| i | 6 | 11.57 | 0.43 | 3.69 | 112.29 | 1.13 |
| İ | 7 [| 14.23 | 0.34 | 9.10 | 186.08 | 1.87 |
| 1 | 8 [| 14.49 | 0.53 | 20.32 | 644.13 | 6.48 |
| | otal | | | | 9940.67 | 100.00 |

¹H NMR of **3d**



¹³C NMR of **3d**



HPLC analysis: rac-3d

Data file: Sample Info: D:\BERT\NI\103AR1W.D Laufmittel: n-Heptan/EtOH 7:3; Die Probe ist in DCM/LM gelöst


Säule: WHELK.M

Säuleninfo: (s,s)-Whelk Ol (250x4,6)mm

Analytik Labor AKEN Operator:


Injektion Time: Injektion Date: 09:20:37 23.01.2015

Instrument Conditions: At Start At Stop Temperature in°C: Pressure in bar: Flow in ml/min: 30.0 31.9 0.5 30.0 32.1




| 1 | ‡ I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|-------------------|-------------------|--------|
| | | I | I | I | I . | I I |
| - 1 | 1 | 10.80 | 1.89 | 4.79 | 543.25 | 5.45 |
| | 2 | 14.31 | 0.41 | 192.17 | 4771.17 | 47.86 |
| - 1 | 3 | 17.88 | 0.47 | 142.52 | 4654.96 | 46.69 |
| T | otal | | | | 9969.38 | 100.00 |

Enantioenriched 3d




| I | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|---|------------|-------------------|-------|----------------|--------------|--------|
| | | I | I | I I | I I | |
| 1 | 1 | 10.89 | 1.22 | 20.42 | 2074.81 | 2.92 |
| 1 | 21 | 14.00 | 0.36 | 530.83 | 13148.85 | 18.53 |
| I | 3 | 17.08 | 0.45 | 1743.92 | 55753.09 | 78.55 |
| т | otal | | | | 70976 74 | 100 00 |

¹H NMR of **3e**



¹³C NMR of **3e**



HPLC analysis: rac-3e

Data file: Sample Info: PACKARD


D:\GONZO\NI\104AR1AD.D Laufmittel: n-Heptan/iPrOH 7:3; Die Probe ist in DCM/LM gelöst.

Säule:

DAICELAD.M Chiralpak AD (250x4,6)mm Analytik Labor AKEN Säuleninfo: Operator:


Injektion Time: Injektion Date: 09:28:07 26.01.2015

Instrument Conditions: Temperature in°C: Pressure in bar: Flow in ml/min: At Start 30.0°C 28.1 0.70 At Stop 30.0°C 28.7 0.70




| 1 | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|---|------|-------------------|-------|-------------------|--------------|--------|
| ¦ | - | 4.56 | 0.18 | 0.16 | 2.11 | 0.12 |
| 1 | 2 | 7.81 | 0.17 | 0.60 | 7.72 | 0.44 |
| i | 3 | 8.06 | 0.30 | 0.95 | 22.01 | 1.24 |
| İ | 4 | 9.14 | 0.36 | 1.65 | 43.35 | 2.45 |
| 1 | 5 | 9.83 | 0.33 | 36.78 | 818.81 | 46.23 |
| i | 61 | 10.88 | 0.30 | 0.90 | 20.50 | 1.16 |
| 1 | 71 | 11.51 | 0.38 | 1.88 | 50.28 | 2.84 |
| 1 | 8 | 14.01 | 0.47 | 25.02 | 806.27 | 45.53 |
| T | otal | | | | 1771.05 | 100.00 |

Enantioenriched 3e




| I | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|----------------|-------------------|--------|
| 1 | | | | | | |
| - 1 | 1 | 6.67 | 0.22 | 16.75 | 245.14 | 1.68 |
| 1 | 2 | 7.15 | 0.30 | 3.10 | 65.99 | 0.45 |
| 1 | 3 | 8.19 | 0.28 | 6.87 | 131.53 | 0.90 |
| 1 | 4 | 9.95 | 0.31 | 69.35 | 1468.18 | 10.05 |
| 1 | 5 | 14.19 | 0.45 | 419.45 | 12700.59 | 86.92 |
| _ | otal | | | | 14611.42 | 100.00 |

¹H NMR of **3f**



¹³C NMR of **3f**



HPLC analysis: rac-3f

Sample Name: Ni 91 A rac


Data file:

E:\BERT\NI\91AROJ.D Laufmittel: n-Heptan/EtOH 8:2; Die Probe ist in DCM/LM gelöst Sample Info:

DAICELOJ.M Säuleninfo: (250 x 4.6) mm 10µ Operator: Analytik Labor AKEN

Injektion Time: Injektion Date: 13:05:15 10.10.2014


Instrument Conditions: At Start At Stop 30.0 42.7 1.0 Temperature in°C: Pressure in bar: Flow in ml/min: 30.0 41.4



Agilent Technologies


| I | ‡ I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------|----------------------|-------|-------------------|-------------------|--------|
| | | I | | I | I I | |
| ٦- | 1 | 17.82 | 1.16 | 118.87 | 9111.51 | 49.25 |
| I | 2 | 24.87 | 1.58 | 89.12 | 9388.86 | 50.75 |
| | otal | | | | 18500.38 | 100.00 |

Enantioenriched 3f




| 1 | # | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|----------|-------------------|-------|-------------------|-------------------|--------|
| 1_ | | | | I | | |
| - 1 | 1 | 6.31 | 1.12 | 6.43 | 536.24 | 1.08 |
| | 2 | 9.60 | 1.32 | 8.53 | 799.00 | 1.61 |
| | 3 | 17.37 | 0.93 | 75.08 | 4677.73 | 9.45 |
| -1 | 4 | 23.61 | 1.55 | 422.18 | 43475.18 | 87.85 |
| 7 | otal | | | | 49488.15 | 100.00 |

¹H NMR of **3g**



¹³C NMR of **3g**



HPLC analysis: rac-3g

Data file: Sample Info:


D:\ERNIE\NI\99ARNW.D Laufmittel: n-Heptan/EtOH 7:3; Die Probe ist in DCM/LM gelöst

Säule: WHELK.M Säuleninfo: (250x4)mm

Operator: Analytik Labor AKEN


11:28:47 27.02.2015 Injektion Time: Injektion Date:

Instrument Conditions: At Start At Stop 30.0 30.0 Temperature in°C: Pressure in bar: Flow in ml/min: 48.1 48.1 0.7




| I | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|-------------------|-------------------|--------|
| | | l I | | I | I | |
| - 1 | 1 | 7.88 | 0.48 | 1.62 | 46.56 | 1.18 |
| | 21 | 8.33 | 0.25 | 131.23 | 1969.85 | 49.93 |
| I | 3 | 14.41 | 0.57 | 56.27 | 1928.99 | 48.89 |
| T | otal | | | | 3945.40 | 100.00 |

Enantioenriched 3g




| I | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------------|-------------------|---------------|------------------|--------------------|----------------|
| | 1 2 | 8.34 14.19 | 0.23 0.46 | 46.77 231.26 | 718.19 7474.65 | 8.77 91.23 |
| To | tal | | | | 8192.84 | 100.00 |

 ^{1}H NMR of 3h



¹³C NMR of **3h**



HPLC analysis: rac-3h

Data file: Sample Info: D:\BERT\NI\98ARW.D Laufmittel: n-Heptan/EtOH 9:1; Die Probe ist in DCM/LM gelöst


WHELK.M

(s,s)-Whelk Ol (250x4,6)mm Säuleninfo:

Analytik Labor AKEN


Injektion Time: Injektion Date: 10:23:16 14.01.2015

At Stop Instrument Conditions: At Start Temperature in°C: 30.0 30.0 Pressure in bar: Flow in ml/min: 52.1 51.6




| 1 | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|-------------------|-------------------|--------|
| | | | | 1 | I | |
| - 1 | 11 | 9.99 | 0.27 | 67.93 | 1225.23 | 49.68 |
| | 2 | 11.86 | 0.33 | 54.97 | 1216.75 | 49.33 |
| - 1 | 3 | 14.94 | 0.64 | 0.64 | 24.43 | 0.99 |
| T | otal | | | | 2466.41 | 100.00 |

Enantioenriched 3h




| 1 | # | 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|---|------|-------|-------------------|-------|-------------------|--------------------|--------|
| - | 1 2 | - | 9.93 | 0.27 | 34.05 251.55 | 612.11 5437.39 | 10.12 |
| | otal | | | | | 6049.50 | 100.00 |

¹H NMR of **3i**



¹³C NMR of **3i**



HPLC analysis: rac-3i

Data file: Sample Info: D:\BERT\NI\95ARW.D Laufmittel: n-Heptan/EtOH 7:3; Die Probe ist in DCM/LM gelöst


WHELK.M

(s,s)-Whelk Ol (250x4,6)mm Säuleninfo:

Analytik Labor AKEN Operator:


Injektion Time: Injektion Date: 09:54:50 09.01.2015

Instrument Conditions: At Start At Stop Temperature in °C: Pressure in bar: Flow in ml/min: 30.0 45.7 0.7 30.0 46.0




| 1 | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|-------------------|-------------------|--------|
| 1_ | | II | | I_ | | I |
| - 1 | 1 | 5.76 | 0.15 | 458.38 | 4175.62 | 49.90 |
| -1 | 2 | 6.78 | 0.18 | 371.93 | 4191.99 | 50.10 |
| T | otal | | | | 8367.61 | 100.00 |

Enantioenriched 3i




| 1 | ‡ 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------------|-------------------|-------|-------------------|-------------------|--------|
| 1 | | | | | | |
| | 1 | 5.79 | 0.16 | 106.36 | 982.88 | 7.43 |
| | 2 | 6.80 | 0.18 | 1095.33 | 12240.82 | 92.57 |
| _ | | | | | | |
| To | tal | | | | 13223.69 | 100.00 |

¹H NMR of **3**j



¹³C NMR of **3j**



HPLC analysis: rac-3j

Data file:

D:\BERT\NI\102ARW.D Laufmittel: n-Heptan/EtOH 7:3; Die Probe ist in DCM/LM gelöst


WHELK.M Säule:

Säuleninfo: (s,s)-Whelk Ol (250x4,6)mm

Analytik Labor AKEN Operator:


08:28:01 23.01.2015 Injektion Time: Injektion Date:

Instrument Conditions: At Start At Stop Temperature in °C: Pressure in bar: Flow in ml/min: 30.0 30.0 46.0 0.7 45.9 0.7




| I | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area 🖁 📗 |
|---|----------|-------------------|---------------|-------------------|-------------------|-----------------|
| _ | 1 2 | 6.66 7.96 | 0.17 0.22 | 189.14 148.08 | 2037.55 | 50.09 49.91 |
| T | otal | | | | 4068.02 | 100.00 |

Enantioenriched 3j




| I | # | 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|-------|-----|----------------------|-------|-------------------|-------------------|--------|
| | | | | | I | I | 1 |
| ı, | | ī,- | 4.89 | 0.13 | 4.61 | 34.53 | 1.82 |
| 1 | | 2 | 6.58 | 0.16 | 14.88 | 156.10 | 8.21 |
| 1 | | 3 | 7.80 | 0.21 | 129.07 | 1689.22 | 88.85 |
| I | | 4 | 12.63 | 0.34 | 0.93 | 21.34 | 1.12 |
| - | Total | | | | | 1901.19 | 100.00 |

 ^{1}H NMR of 3k



¹³C NMR of **3k**



HPLC analysis: rac-3k

Data file: Sample Info:

D:\BERT\NI\97ARW.D Laufmittel: n-Heptan/EtOH 9:1; Die Probe ist in DCM/LM gelöst

4.


Säule: Säuleninfo:

WHELK.M (s,s)-Whelk O1 (250x4,6)mm

Analytik Labor AKEN Operator:


Injektion Time: Injektion Date: 09:59:55 14.01.2015

Instrument Conditions: At Start At Stop Temperature in °C: Pressure in bar: Flow in ml/min: 30.0 52.0 1.0 30.0 52.0 1.0




| 1 | # | Ret. T (min) | ime | I | Width | I | Height (mAU) | I | Area (mAU*s) | 1 | Area | 8 |
|---|------|-----------------|-----|---|-------|-----|--------------|------|-----------------|-----|------|--------|
| 1 | | | | | | | | 1 | | | | 1 |
| | 1 | | 5.7 | 0 | 0.3 | 14 | 609 | .971 | 5753 | .59 | | 49.57 |
| | 2 | | 6.9 | 7 | 0.3 | 181 | 478 | .981 | 5750 | .17 | | 49.54 |
| 1 | 3 | | 8.6 | 3 | 0.4 | 43 | 4 | .001 | 102 | .21 | | 0.88 |
| T | otal | | | | | | | | 11605 | .97 | | 100.00 |

Enantioenriched 3k




| 1 | ‡ I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|----------|----------------------|-------|--------------------|----------------------|----------------|
| - | 1 2 | 5.68 6.78 | 0.14 | 437.13 3377.56 | 4070.50 44406.45 | 8.40 91.60 |
| To | tal | | | | 48476.95 | 100.00 |

¹H NMR of **31**



¹³C NMR of **31**



HPLC analysis: rac-31

PACKARD Data file: Sample Info:


D:\GONZO\NI\110AR1OD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst

Säule:

DAICELOD.M Chiralcel OD (250x4,6)mm Analytik Labor AKEN Säuleninfo: Operator:


Injektion Time: Injektion Date: 11:45:28 03.02.2015

Instrument Conditions: At Start
Temperature in°C: 30.0°C
Pressure in bar: 25.1
Flow in ml/min: 0.70 At Stop 30.0°C 24.8 0.70




| 1 | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|------|-------------------|-------|-------------------|-------------------|--------|
| | | 1 | | | | |
| - 1 | 1 | 6.67 | 0.23 | 9.07 | 145.59 | 0.91 |
| i. | 2 | 11.06 | 0.38 | 303.10 | 7919.58 | 49.43 |
| -1 | 3 | 12.72 | 0.44 | 260.29 | 7956.14 | 49.66 |
| Т | otal | | | | 16021.30 | 100.00 |

Enantioenriched 31




| I | ‡ | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----------------|----------|-------------------|-------|----------------|-------------------|--------|
| 1_ | | | | | | |
| | 1 | 4.34 | 0.17 | 0.801 | 8.87 | 0.53 |
| 1 | 2 | 5.10 | 0.16 | 0.92 | 10.23 | 0.61 |
| 1 | 3 | 5.47 | 0.17 | 0.63 | 7.49 | 0.44 |
| 1 | 4 | 11.10 | 0.39 | 55.16 | 1464.45 | 86.93 |
| I | 5 | 12.78 | 0.44 | 6.32 | 193.52 | 11.49 |
| _ _ | otal | | | | 1604 55 | 100.00 |

¹H NMR of **3m**



¹³C NMR of **3m**



HPLC analysis: rac-3m

PACKARD


Data file: Sample Info: D:\GONZO\NI\105ARAD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst.

Säule:

DAICELAD.M Chiralpak AD (250x4,6)mm Analytik Labor AKEN Säuleninfo: Operator:


Injektion Time: Injektion Date: 07:50:49 27.01.2015

Instrument Conditions: Temperature in°C: Pressure in bar: Flow in ml/min: At Start 30.0°C 32.5 At Stop 30.0°C 33.1 1.00 1.00




| I | # R | et. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|-------|--------------------|-------|----------------|-------------------|--------|
| | | | | I | II | |
| | 1 | 3.18 | 0.11 | 0.83 | 5.92 | 0.21 |
| 1 | 2 | 3.69 | 0.17 | 0.50 | 5.98 | 0.21 |
| 1 | 3 | 4.41 | 0.15 | 1.40 | 15.23 | 0.53 |
| 1 | 4 | 4.84 | 0.35 | 1.41 | 34.34 | 1.20 |
| - 1 | 5 | 5.16 | 0.17 | 2.02 | 23.57 | 0.82 |
| i | 6 | 8.72 | 0.29 | 70.51 | 1387.88 | 48.55 |
| 1 | 7 | 11.99 | 0.41 | 50.24 | 1385.79 | 48.48 |
| To | tal | | | | 2858.71 | 100.00 |

Enantioenriched 3m




| I | # 1 | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|---|------|-------------------|-------|----------------|-------------------|--------|
| | | | 1 | | | |
| 1 | 11 | 4.41 | 0.13 | 16.97 | 156.10 | 0.84 |
| 1 | 2 | 4.84 | 0.14 | 61.24 | 599.81 | 3.23 |
| 1 | 3 | 7.07 | 0.24 | 4.82 | 76.71 | 0.41 |
| 1 | 4 | 8.66 | 0.28 | 99.57 | 1903.06 | 10.25 |
| 1 | 5 | 11.94 | 0.40 | 589.74 | 15837.20 | 85.27 |
| T | otal | | | | 18572.88 | 100.00 |

¹H NMR of **3n**



¹³C NMR of **3n**



HPLC analysis: rac-3n


D:\GONZO\NI\106ARAD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst. PACKARD Data file: Sample Info:

Säule: Säuleninfo:

DAICELAD.M Chiralpak AD (250x4,6)mm Analytik Labor AKEN Operator:


Injektion Time: Injektion Date: 08:19:00 27.01.2015

Instrument Conditions: At Start
Temperature in°C: 30.0°C
Pressure in bar: 32.4
Flow in ml/min: 1.00 At Stop 30.0°C 32.8 1.00




| 1 | # | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|----------|-------------------|-------|----------------|-------------------|--------|
| 1 | | | | | | |
| - 1 | 1 | 4.40 | 0.15 | 6.37 | 68.80 | 0.76 |
| 1 | 2 | 5.38 | 0.17 | 2.38 | 27.90 | 0.31 |
| 1 | 3 | 9.18 | 0.31 | 211.80 | 4477.86 | 49.26 |
| I | 4 | 12.75 | 0.45 | 149.06 | 4515.36 | 49.67 |
| 1 | otal | | | | 9089.92 | 100.00 |

Enantioenriched 3n




| I | # I | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|------------|-------------------|-------|----------------|-------------------|--------|
| 1_ | | | | | | |
| | 1 | 3.19 | 0.13 | 0.83 | 7.24 | 0.34 |
| | 2 | 3.68 | 0.11 | 0.85 | 6.34 | 0.30 |
| | 3 | 4.41 | 0.14 | 0.53 | 5.10 | 0.24 |
| | 4 | 9.23 | 0.30 | 12.44 | 255.68 | 11.95 |
| 1 | 5 | 12.83 | 0.44 | 63.69 | 1864.46 | 87.17 |
| _ | | | | | 2120 02 | 100.00 |

¹H NMR of **30**



¹³C NMR of **30**




HPLC analysis: rac-30

Data file: Sample Info: D:\GONZO\NI\112AROD.D Laufmittel: n-Heptan/iPrOH 9:1; Die Probe ist in DCM/LM gelöst PACKARD

DAICELOD.M Chiralcel OD (250x4,6)mm Analytik Labor AKEN Säule: Säuleninfo: Operator:


Injektion Time: Injektion Date: 17:24:19 02.02.2015

Instrument Conditions: Temperature in°C: Pressure in bar: Flow in ml/min: At Start 30.0°C 35.5 At Stop 30.0°C 35.8



| 1 | ‡ | Ret. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|-----|----------|-------------------|-------|----------------|-------------------|--------|
| | | 1 | 1 | | | 1 |
| - 1 | 1 | 8.48 | 0.32 | 247.92 | 5339.45 | 50.11 |
| 1 | 2 | 12.16 | 0.47 | 164.76 | 5316.61 | 49.89 |
| | otal | | | | 10656.06 | 100.00 |

Enantioenriched 30



| I | # F | let. Time (min) | Width | Height (mAU) | Area (mAU*s) | Area % |
|----|-------|---------------------|-------|-------------------|--------------|--------|
| 1_ | | | | | | |
| 1 | 1 | 8.50 | 0.32 | 72.56 | 1599.90 | 10.72 |
| I | 2 | 12.16 | 0.50 | 396.27 | 13318.11 | 89.28 |
| T | otal | | | | 14918.01 | 100.00 |